Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD3 antibody and IL-2 complex combination therapy inhibits atherosclerosis by augmenting a regulatory immune response.

Journal of the American Heart Association - 22 Apr 2014

Kasahara Kazuyuki, Sasaki Naoto, Yamashita Tomoya, Kita Tomoyuki, Yodoi Keiko, Sasaki Yoshihiro, Takeda Masafumi, Hirata Ken-Ichi

Abstract excerpt

BACKGROUND: Accumulating evidence suggests that the balance between pathogenic effector T cells (Teffs) and regulatory T cells (Tregs) may be important for controlling atherosclerotic disease. We hypothesized that a combination therapy with anti-CD3 antibody (CD3-Ab) and IL-2/anti-IL-2 monoclonal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents
Share to Antigen-Antibody Complex

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aortic Diseases

Share to CD3 Complex

Share to Cholesterol, Dietary

Share to Immunity, Cellular

Share to T-Lymphocytes, Helper-Inducer

Source

Open in PubMed Open full text

Identifiers

PMID: 24755152
DOI: 10.1161/JAHA.113.000719
PMCID: PMC4187475

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24755152-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD3 antibody and IL-2 complex combination therapy inhibits atherosclerosis by augmenting a regulatory immune response.PMID 24755152Read ↗

Treating atherosclerosis with regulatory T cells.Semantic proximity Read ↗

B Cell–Activating Factor Neutralization Aggravates AtherosclerosisSemantic proximity Read ↗

Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice.Semantic proximity Read ↗

Effects of BAFF Neutralization on Atherosclerosis Associated With Systemic Lupus Erythematosus.Semantic proximity Read ↗

Activation of the Regulatory T-Cell/Indoleamine 2,3-Dioxygenase Axis Reduces Vascular Inflammation and Atherosclerosis in Hyperlipidemic Mice.Semantic proximity Read ↗

B Cell and CD4 T Cell Interactions Promote Development of AtherosclerosisSemantic proximity Read ↗

Macrophage beta3 integrin suppresses hyperlipidemia-induced inflammation by modulating TNFalpha expression.Semantic proximity Read ↗

Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression.Semantic proximity Read ↗

Targeting B cells in atherosclerosis: closing the gap from bench to bedside.Semantic proximity Read ↗

Overexpression of Cytotoxic T-Lymphocyte-Associated Antigen-4 Prevents Atherosclerosis in Mice.Semantic proximity Read ↗

Bone marrow angiotensin AT2 receptor deficiency aggravates atherosclerosis development by eliminating macrophage liver X receptor-mediated anti-atherogenic actions.Semantic proximity Read ↗

Follicular regulatory helper T cells control the response of regulatory B cells to a high-cholesterol diet.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.